Innovative Health Sciences (IHS) proudly announces a remarkable milestone in its journey to introduce the Insignis™ Infusion ...

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

If LEQEMBI subcutaneous maintenance dosing is approved by the FDA ... 46 70 410 71 80 About lecanemab (Leqembi ®) Lecanemab is the result of a strategic research alliance between BioArctic and Eisai.

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...

PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global immunoglobulin market is experiencing significant growth, driven by the increasing prevalence of immune-related diseases and ...

The final, formatted version of the article will be published soon. Immunoglobulin replacement therapy (IgRT), either intravenous (IVIg) or subcutaneous (SCIg), is crucial for managing primary immune ...

Hyaluronidase is an enzyme that facilitates subcutaneous absorption of the active drug nivolumab. The subcutaneous version could transform the way care is delivered to patients, as it allows ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

Global pharmaceutical companies are rapidly changing cancer treatment injections. The advent of subcutaneous (SC) formulations, which dramatically reduce administration time compared to ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).